Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Back

SW/PSYCH
Symposium

S20--ETI & Mental Health: Current Lay of the Land & New Horizons

Friday, September 27, 2024
2:30 PM – 4:30 PM ET
Location:102 AB

Recorded Session

This symposium will focus on the state of the science on the intersection of elexacaftor/tezacaftor/ivacaftor (ETI) and mental/behavioral health symptoms for persons with cystic fibrosis. Speakers will review the latest findings on the associations between ETI use and mental health and/or neurocognitive symptoms across the translational science spectrum, present pediatric- and adult-focused studies that aim to better understand potential mental/behavioral health side-effects and other sequelae of ETI use, discuss strategies to manage mental/behavioral health side effects and related concerns, and discuss future directions for the field.

Learning Objectives:

  • Generally summarize the extent (e.g., size and quality) of the ETI and mental health literature for adult and pediatric populations with CF.
  • Identify at least 2 approaches to symptom management in terms of mental/behavioral health concerns raised in the context of ETI use.
  • Explain at least one unintended mental/behavioral health-related sequelae of ETI use.

Presentations:

  • 2:30 PM – 4:30 PM ET
    S20.1- Mind Matters: The Evolving Science of Elexacaftor/Tezacaftor/Ivacaftor & Mental Health

    Speaker: CJ Bathgate, PhD (she/her/hers) – National Jewish Health

  • 2:30 PM – 4:30 PM ET
    S20.2- Mental & Behavioral Health Among Children on ETI: Preliminary Findings from the yETI Study

    Speaker: Robin S. Everhart, PhD (she/her/hers) – Virginia Commonwealth University

    Speaker: Emily Muther, PhD (she/her/hers) – Child Psychiatry

  • 2:30 PM – 4:30 PM ET
    S20.3 General Mental Health Screener (GEMS-CF): Mental Health Concerns Related to CFTR Modulators

    Speaker: Beth A. Smith, MD (she/her/hers) – Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • 2:30 PM – 4:30 PM ET
    S20.4- Strategies to Manage Neuropsychiatric Symptoms Associated with CFTR modulators

    Speaker: Anna Georgiopoulos, MD (she/her/hers) – Massachusetts General Hospital, Boston, MA, USA

  • 2:30 PM – 4:30 PM ET
    S20.5- TIDES 2.0: Is it Time to Screen Mental Health in Younger Children?

    Speaker: Alexandra L. Quittner, PhD (she/her/hers) – Joe DiMaggio Cystic Fibrosis Center